WO2010129636A3 - Lenalidomide polymorph - Google Patents

Lenalidomide polymorph Download PDF

Info

Publication number
WO2010129636A3
WO2010129636A3 PCT/US2010/033661 US2010033661W WO2010129636A3 WO 2010129636 A3 WO2010129636 A3 WO 2010129636A3 US 2010033661 W US2010033661 W US 2010033661W WO 2010129636 A3 WO2010129636 A3 WO 2010129636A3
Authority
WO
WIPO (PCT)
Prior art keywords
lenalidomide
polymorph
preparation
polymorphic form
processes
Prior art date
Application number
PCT/US2010/033661
Other languages
French (fr)
Other versions
WO2010129636A2 (en
Inventor
Srinivasulu Rangineni
Vamsi Krishna Muppidi
Shakti Singh
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2010129636A2 publication Critical patent/WO2010129636A2/en
Publication of WO2010129636A3 publication Critical patent/WO2010129636A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to a crystalline polymorphic form of lenalidomide, processes for preparation thereof, and the use of the polymorphic form in the preparation of pharmaceutical compositions.
PCT/US2010/033661 2009-05-08 2010-05-05 Lenalidomide polymorph WO2010129636A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1079CH2009 2009-05-08
IN1079/CHE/2009 2009-05-08
US22652409P 2009-07-17 2009-07-17
US61/226,524 2009-07-17

Publications (2)

Publication Number Publication Date
WO2010129636A2 WO2010129636A2 (en) 2010-11-11
WO2010129636A3 true WO2010129636A3 (en) 2011-03-31

Family

ID=43050836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/033661 WO2010129636A2 (en) 2009-05-08 2010-05-05 Lenalidomide polymorph

Country Status (2)

Country Link
AR (1) AR076856A1 (en)
WO (1) WO2010129636A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (en) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione and methods of making the same
WO2011061611A1 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2012127493A1 (en) 2011-03-23 2012-09-27 Hetero Research Foundation Polymorphs of lenalidomide
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3744318A1 (en) * 2015-08-27 2020-12-02 Grindeks, A Joint Stock Company Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications
TWI664172B (en) * 2016-08-25 2019-07-01 大陸商浙江海正藥業股份有限公司 Crystal form of lenalidomide, preparation method and application thereof
CN112999224B (en) * 2021-03-03 2022-09-16 天津大学 Ibuprofen-loaded lenalidomide composite particle and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517A (en) * 1996-07-24 1997-06-03 Celgene Corporation Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
WO2005023192A2 (en) * 2003-09-04 2005-03-17 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517A (en) * 1996-07-24 1997-06-03 Celgene Corporation Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
WO2005023192A2 (en) * 2003-09-04 2005-03-17 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7465800B2 (en) * 2003-09-04 2008-12-16 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20090062343A1 (en) * 2003-09-04 2009-03-05 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
WO2010129636A2 (en) 2010-11-11
AR076856A1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
WO2010129636A3 (en) Lenalidomide polymorph
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
HK1131777A1 (en) Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
SI2220152T1 (en) Process for the preparation of a crosslinker composition
AP3050A (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
HK1155742A1 (en) Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
EP2216333A3 (en) Crystalline forms of Dexlansoprazole
PT2504331E (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
IL218044A (en) (trihalophenyl-methyl)-(1-halophenyl-2-imidazolyl-ethyl)-ethers, process for their preparation and pharmaceutical compositions comprising them
WO2011023954A3 (en) Polymorphic forms of manidipine
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
ZA201203531B (en) Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof
WO2011100282A3 (en) Imatinib mesylate polymorphs
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10772742

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10772742

Country of ref document: EP

Kind code of ref document: A2